Jaguar Health Inc. (JAGX) Financial Statements (2024 and earlier)

Company Profile

Business Address 200 PINE STREET SUITE 400
SAN FRANCISCO, CA 94104
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6,4695,469 8,0903,4952,568
Cash and cash equivalents6,4695,469 8,0903,4952,568
Restricted cash and investments     388 
Receivables2,1842,4672,1444,5601,6951,002
Inventory, net of allowances, customer advances and progress billings9,1897,0244,9002,7822,1293,342
Inventory9,1897,0244,9002,7822,1293,342
Deferred costs   13   
Other undisclosed current assets10,1217,36121,3772,3601,8161,238
Total current assets:27,96322,32128,43417,7929,5228,150
Noncurrent Assets
Operating lease, right-of-use asset1,1761,1401,084  
Property, plant and equipment496557650677710761
Intangible assets, net (including goodwill)20,11622,43922,65124,33726,02431,711
Intangible assets, net (excluding goodwill)20,11622,43922,65124,33726,02431,711
Other undisclosed noncurrent assets1,01299544637154421
Total noncurrent assets:22,80025,13124,83125,05126,88832,892
TOTAL ASSETS:50,76347,45253,26542,84336,41041,042
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,77213,97312,0469,2528,27410,354
Accounts payable4,9745,8084,9294,7595,3525,414
Accrued liabilities3,7988,1657,1174,4932,9224,939
Deferred revenue     
Debt4,86715,8833,1843,7897,1154,846
Other undisclosed current liabilities348483241179311,460
Total current liabilities:13,98730,33915,47113,22015,39226,659
Noncurrent Liabilities
Long-term debt and lease obligation30,99317,74425,94112,421450 
Long-term debt, excluding current maturities30,99317,74425,02212,421450 
Liabilities, other than long-term debt886725    
Deferred revenue     
Operating lease, liability886725919  
Other undisclosed noncurrent liabilities   (919)   
Total noncurrent liabilities:31,87918,46925,94112,421450 
Total liabilities:45,86648,80841,41225,64115,84226,659
Temporary equity, carrying amount     9,000
Equity
Equity, attributable to parent, including:4,954(657)11,60717,20210,6745,383
Additional paid in capital313,854266,971231,100184,090142,04699,927
Accumulated other comprehensive loss(652)(680)    
Accumulated deficit(308,248)(266,948)(219,494)(166,899)(133,090)(94,551)
Warrants and rights outstanding   1 3 
Other undisclosed equity, attributable to parent    111,7146
Equity, attributable to noncontrolling interest(64)(699)242   
Other undisclosed equity7 4 9,894 
Total equity:4,897(1,356)11,85317,20220,5685,383
TOTAL LIABILITIES AND EQUITY:50,76347,45253,26542,84336,41041,042

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues  11,956 9,3855,7754,416
Cost of revenue(2,037)(2,019)(2,333)(3,280)(3,816)(2,766)
Gross profit:(2,037)9,937(2,333)6,1051,9591,650
Operating expenses(42,015)(44,352)(41,076)(27,409)(30,259)(35,240)
Other undisclosed operating income (loss)9,761 2,701(5,343)(649)2,766
Operating loss:(34,291)(34,415)(40,708)(26,647)(28,948)(30,824)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
200950(765)19081316
Interest and debt expense(2,685)(14,910)(9,174)(4,656)(10,672)(3,173)
Loss from continuing operations before equity method investments, income taxes:(36,776)(48,375)(50,647)(31,113)(39,539)(33,681)
Other undisclosed income (loss) from continuing operations before income taxes(5,125)(20)(1,953)(2,696)1,0091,535
Loss from continuing operations before income taxes:(41,901)(48,395)(52,600)(33,809)(38,529)(32,146)
Income tax expense     (10) 
Loss from continuing operations:(41,901)(48,395)(52,600)(33,809)(38,539)(32,146)
Loss before gain (loss) on sale of properties:(52,600)(33,809)(38,539)(32,146)
Net loss:(41,901)(48,395)(52,600)(33,809)(38,539)(32,146)
Net income attributable to noncontrolling interest6019415   
Net loss attributable to parent:(41,300)(47,454)(52,595)(33,809)(38,539)(32,146)
Preferred stock dividends and other adjustments      (995)
Other undisclosed net income available to common stockholders, basic      995
Net loss available to common stockholders, diluted:(41,300)(47,454)(52,595)(33,809)(38,539)(32,146)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(41,901)(48,395)(52,600)(33,809)(38,539)(32,146)
Other comprehensive income31     
Other undisclosed comprehensive loss  (680)    
Comprehensive loss:(41,870)(49,075)(52,600)(33,809)(38,539)(32,146)
Comprehensive income, net of tax, attributable to noncontrolling interest5989415   
Comprehensive loss, net of tax, attributable to parent:(41,272)(48,134)(52,595)(33,809)(38,539)(32,146)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: